TIGIT
TIGIT is an immune brake that looked promising, then failed in several big lung cancer trials. It is a cautionary tale.
Tiragolumab (SKYSCRAPER-01), domvanalimab, and others largely failed to add to PD-1/PD-L1 blockade in NSCLC and SCLC in phase 3. Fc-enabled versus Fc-silent design and patient selection remain debated; some programmes continue.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TIGIT is an immune brake that looked promising, then failed in several big lung cancer trials. It is a cautionary tale.
- 1 · What it is
TIGIT is an immune brake that looked promising, then failed in several big lung cancer trials. It is a cautionary tale.
- 2 · What goes wrong in cancer
Binds PVR (CD155) on tumour cells; competes with the activating receptor CD226.
- 3 · How drugs use it
1 product aims at TIGIT: antibodies. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
Biology
Binds PVR (CD155) on tumour cells; competes with the activating receptor CD226.
- T and NK cells
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | n/a | Immune-cell target; PD-L1 used for selection | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"TIGIT" OR ABSTRACT:"TIGIT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIGIT, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetLAG-3
Shares TIM-3, Immune checkpoint, T-cell exhaustion, PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag checkpoint.
- TargetCD47
Shares Cold tumours and the immunosuppressive microenvironment and the tags checkpoint, failed-so-far.
- ProductFianlimab
Shares T-cell exhaustion, Immune checkpoint inhibitors and the tag failed-so-far.
- TargetCTLA-4
Shares Immune checkpoint, T-cell exhaustion, PD-1 / PD-L1 immune checkpoint & T-cell activation, Cold tumours and the immunosuppressive microenvironment and the tag checkpoint.
- TargetPD-1
Shares TIM-3, Immune checkpoint, T-cell exhaustion, NK-cell recognition: missing self & stress ligands and the tag checkpoint.
- TargetPD-L1
Shares Caution: TIGIT + PD-(L)1 blockade, Tiragolumab, Immune checkpoint, T-cell exhaustion and the tag checkpoint.
- TargetVISTA
Shares TIM-3, PD-1 / PD-L1 immune checkpoint & T-cell activation, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TermHallmark: avoiding immune destruction
Shares Immune checkpoint, T-cell exhaustion, NK-cell recognition: missing self & stress ligands, PD-1 / PD-L1 immune checkpoint & T-cell activation.